Dr. Helen Hobbs // 2016
Lipid Metabolism and Fatty Liver Disease
Dr. Hobbs won the 2016 Breakthrough Prize in Life Sciences in recognition of transformative genetics research techniques she developed and used to identify key genes involved in lipid metabolism and fatty liver disease. In 2000, Dr. Hobbs co-launched the Dallas Heart Study, a multiethnic population-based study of several thousand individuals in Dallas County. While other genetics researchers were focused on finding common differences in the genome that contribute to particular traits, Dr. Hobbs and her colleague, Dr. Jonathan focused on rare genetic variants, believing that understanding these “exceptions” could more quickly lead to biomedical breakthroughs. Together, they showed that individuals with inactivating mutations in the PCSK9 gene have a markedly reduced incidence of heart disease, a discovery that led to the development by drug companies of a stunningly effective class of drugs for lowering LDL cholesterol. Using data from the Dallas Heart Study, the two also discovered that certain variants of two genes are both strongly associated with fat accumulation in the liver. Subsequently, it has been shown that the same sequence variations are also associated with liver inflammation, cirrhosis, and liver cancer. Dr. Hobbs’ rare-variant or low-variant approach is now emulated by researchers worldwide.